Results 271 to 280 of about 1,125,014 (336)

A RETROSPECTIVE CLINICAL STUDY OF RELAPSED PROSTATIC CANCER

, 1987
Hiroshi Takigawa, Susumu Kagawa, Yoichi Aga, Kazuo Kurokawa, T. J. P. I. B. D. research Group   +4 more
openalex   +2 more sources

COPS5 Triggers Ferroptosis Defense by Stabilizing MK2 in Hepatocellular Carcinoma

Advanced Science, EarlyView.
COPS5, which is overexpressed in HCC in an amplification‐ and ATF4‐dependent manner, stabilizes MK2 through deubiquitination and, in turn, induces HSPB1 activation, protecting HCC cells from ferroptosis and thus promoting sorafenib resistance and tumor progression. Abstract Sorafenib, which is proven to serve as a potent ferroptosis inducer, is used as
Ai‐Ling Luo, Wen‐Ying Zheng, Qiong Zhang, Yan Yuan, Mei‐Qi Li, Kai Du, An‐Ran Gao, Li‐Jun Pei, Jie Xie, Wen‐Hao Chen, Long Zhang, Xiu‐Zhu Guo, Xiao‐Ran Yang, Chao Zeng, Guo‐Hua Yang, Min Deng   +15 more
wiley   +1 more source

The Accuracy of Biparametric Prostate MRI in the Pathway of Patients With Prostate Cancer. [PDF]

Cureus
Ion RT, Serbanoiu A, Salcianu AI, Popa MN, Filipoiu FM, Bratu AM.   +5 more
europepmc   +1 more source

Gelsolin's Protective Role in MASH through F‐Actin Regulation and P53 Degradation

Advanced Science, EarlyView.
Gelsolin (GSN) maintains liver metabolic homeostasis by promoting MDM2‐mediated P53 degradation and inhibiting F‐actin/Yes‐associated protein (YAP) overactivation. Loss of GSN impairs P53 degradation, increases lipid deposition, and enhances YAP‐driven fibrosis and inflammation in metabolic‐associated steatohepatitis.
Yiwei Lu, Tong Ji, Zhichao Ye, Jianing Yan, Chao Wang, Jiachen Chen, Ziyang Jin, Yongji Zhu, Xiujun Cai, Yifan Wang   +9 more
wiley   +1 more source

Targeting Prostate Cancer Cells by an Isopeptidase Inhibitor NSC632839. [PDF]

Urol Res Pract
Demir U, Erdogdu R.
europepmc   +1 more source

Nuclear‐Localized BCKDK Facilitates Homologous Recombination Repair to Support Breast Cancer Progression and Therapy Resistance

Advanced Science, EarlyView.
Under DNA damage, tumor cells rely on efficient DNA repair for survival and therapy resistance. This study has demonstrated that BCKDK localizes to breast cancer cell nuclei, where it binds to and phosphorylates RNF8, thereby blocking ubiquitin‐mediated degradation of RAD51 and enhancing HRR. A selective BCKDK inhibitor synergizes with clinical agents,
Haiying Liu, Jiaqian Feng, Tingting Pan, Pinggen Zhang, Ling Ye, Zetan Jiang, Zilong Zhou, Qiankun Mao, Jian Li, Xinyi Yang, Ping Gao, De Huang, Huafeng Zhang   +12 more
wiley   +1 more source

The Impact of Diet and Nutrition on Prostate Cancer - Food for Thought? [PDF]

Curr Oncol Rep
Babakhanlou R, Gowin K.
europepmc   +1 more source

SCORT–Cas13d Nanotherapy Precisely Targets the ‘Undruggable’ Transcription Factor HoxB13 in Metastatic Prostate Cancer In Vivo

Advanced Science, EarlyView.
SCORT–Cas13d–pre‐gHoxB13 lipid nanoparticles precisely deliver Cas13d mRNA and guide RNAs to metastatic prostate tumors in the liver, knocking down the “undruggable” transcription factor HoxB13. This approach suppresses metastatic tumor growth, extends mouse survival, and does not induce major organ toxicity or immune activation, offering a safe and ...
Zhifen Cui, Furong Huang, Kun Fang, Jingyue Yan, Yuebao Zhang, Diana D. Kang, Yufan Zhou, Yue Zhao, Jeffrey I. Everitt, William Hankey, Andrew J Armstrong, Jiaoti Huang, Hongyan Wang, Victor X. Jin, Yizhou Dong, Qianben Wang   +15 more
wiley   +1 more source

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy

Advanced Science, EarlyView.
This study develops a dimeric T cell receptor engager protein specific for tumor KRAS‐G12V mutation. The engager proteins are capable of mediating the formation of synapse between T cell and tumor cell and demonstrate substantial tumor suppression efficacy.
Keke Ma, Jie Wang, Min Jiang, Juanhua He, Fangyang Li, Dan Lu, Chao Su, Yan Chai, Wenjing Jin, Yu Chen, Catherine W.H. Zhang, Xiaopeng Ma, Hui Tan, George F. Gao, Shuguang Tan   +14 more
wiley   +1 more source